ticlopidine has been researched along with Blood Poisoning in 11 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a case of ticlopidine-induced profound neutropenia early in the course of therapy, which was manifest as a febrile systemic illness mimicking sepsis." | 8.80 | Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement. ( Lenihan, DJ; Lewis, P; Ochoa, AB; Wolfe, M, 1998) |
| " We analysed adverse events (AEs) consistent with either pulmonary infection or sepsis, and subsequent mortality, in 18,421 PLATO patients treated with ticagrelor or clopidogrel." | 6.79 | Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. ( Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J, 2014) |
| "We report a case of ticlopidine-induced profound neutropenia early in the course of therapy, which was manifest as a febrile systemic illness mimicking sepsis." | 4.80 | Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement. ( Lenihan, DJ; Lewis, P; Ochoa, AB; Wolfe, M, 1998) |
| "Using a mouse model of intra-abdominal sepsis and acute lung injury, we investigated the role of the P2Y12 receptor in neutrophil migration and lung inflammation in P2Y12 null mice and in mice pretreated with the P2Y12 antagonist clopidogrel." | 3.83 | P2Y12 Receptor Modulates Sepsis-Induced Inflammation. ( Kilpatrick, LE; Kunapuli, SP; Liverani, E; Rico, MC; Tsygankov, AY, 2016) |
| "Analyzing medical records of 979 patients with severe sepsis or septic shock provided some evidence that the use of low-dose aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) was associated with decreased hospital mortality." | 3.79 | Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. ( Boettel, J; Lösche, W; Otto, GP; Sossdorf, M; Winning, J, 2013) |
| " We analysed adverse events (AEs) consistent with either pulmonary infection or sepsis, and subsequent mortality, in 18,421 PLATO patients treated with ticagrelor or clopidogrel." | 2.79 | Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. ( Åsenblad, N; Becker, RC; Cannon, CP; Held, C; Husted, SE; James, SK; Siegbahn, A; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L; Ycas, J, 2014) |
| "Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon." | 2.41 | Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. ( Fragopanagou, E; Galani, A; Giannakoulas, N; Kouraklis-Symeonidis, A; Matsouka, P; Seimeni, U; Symeonidis, A; Tiniakou, M; Zoumbos, N, 2002) |
| "Atherosclerosis is considered as a moderate systemic inflammation and we hypothesise that this chronic condition could have an impact on the outcome in sepsis." | 1.39 | Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. ( Boettel, J; Breuel, H; Kabisch, B; Lösche, W; Otto, GP; Sossdorf, M; Winning, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Storey, RF | 1 |
| James, SK | 1 |
| Siegbahn, A | 1 |
| Varenhorst, C | 1 |
| Held, C | 1 |
| Ycas, J | 1 |
| Husted, SE | 1 |
| Cannon, CP | 1 |
| Becker, RC | 1 |
| Steg, PG | 1 |
| Åsenblad, N | 1 |
| Wallentin, L | 1 |
| Iskandar, MZ | 1 |
| Chong, V | 1 |
| Hutcheon, S | 1 |
| Serebruany, VL | 1 |
| Liverani, E | 1 |
| Rico, MC | 1 |
| Tsygankov, AY | 1 |
| Kilpatrick, LE | 1 |
| Kunapuli, SP | 1 |
| Alosh, M | 1 |
| Huque, MF | 1 |
| Bretz, F | 1 |
| D'Agostino, RB | 1 |
| Seidel, M | 1 |
| Winning, J | 3 |
| Claus, RA | 1 |
| Bauer, M | 1 |
| Lösche, W | 3 |
| Otto, GP | 2 |
| Sossdorf, M | 2 |
| Boettel, J | 2 |
| Kabisch, B | 1 |
| Breuel, H | 1 |
| Symeonidis, A | 1 |
| Kouraklis-Symeonidis, A | 1 |
| Seimeni, U | 1 |
| Galani, A | 1 |
| Giannakoulas, N | 1 |
| Fragopanagou, E | 1 |
| Tiniakou, M | 1 |
| Matsouka, P | 1 |
| Zoumbos, N | 1 |
| Ochoa, AB | 1 |
| Wolfe, M | 1 |
| Lewis, P | 1 |
| Lenihan, DJ | 1 |
| Korkmaz, ME | 1 |
| Cekin, AH | 1 |
2 reviews available for ticlopidine and Blood Poisoning
| Article | Year |
|---|---|
Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.
Topics: Age Distribution; Aged; Aged, 80 and over; Agranulocytosis; Anemia, Aplastic; Anti-Bacterial Agents; | 2002 |
Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement.
Topics: Coronary Angiography; Coronary Disease; Diagnosis, Differential; Female; Follow-Up Studies; Humans; | 1998 |
1 trial available for ticlopidine and Blood Poisoning
| Article | Year |
|---|---|
Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study.
Topics: Adenosine; Aged; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Platelet A | 2014 |
8 other studies available for ticlopidine and Blood Poisoning
| Article | Year |
|---|---|
Acute spinal cord compression: a rare complication of dual antiplatelet therapy.
Topics: Acute Disease; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Fatal Outcome; Female; Hematom | 2015 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mor | 2015 |
P2Y12 Receptor Modulates Sepsis-Induced Inflammation.
Topics: Acute Lung Injury; Animals; Blood Platelets; Clopidogrel; Cytokines; Genetic Predisposition to Disea | 2016 |
Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials.
Topics: Aspirin; Clopidogrel; Data Interpretation, Statistical; Humans; Models, Statistical; Myocardial Infa | 2017 |
Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis.
Topics: Animals; Clopidogrel; Mice; Platelet Aggregation Inhibitors; Sepsis; Ticlopidine | 2009 |
Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Blood Coagulation; Clopidog | 2013 |
Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Dose-Response Relationship, Dru | 2013 |
Bone marrow suppression and klebsiella pneumonia septicemia due to ticlopidine and successful treatment with filgrastim; a case report.
Topics: Biopsy, Needle; Bone Marrow; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating F | 1998 |